by Nicole Foti

You may have noticed the recent hype surrounding the “little pink pill” or “pink Viagra,” a pill used to treat female sexual dysfunction, or FSD, a condition affecting nearly 50 million women nationwide. The FDA’s latest rejection of the drug flibanserin has caught the attention of a number of media outlets and women’s groups, including the National Organization for Women (NOW), who are questioning the motives behind this decision. Why does the FDA refuse to approve any drugs for women with sexual dysfunction, while men have five to choose from, plus another nineteen generic brands of these drugs? After reading many articles indicating that FSD was, in fact, an epidemic affecting millions of women (possibly myself included) and that the FDA was being outright sexist in their reluctance to approve drugs to treat it, I decided to do a little research. Instead of finding answers though, I seem to be left with questions. One in particular is: what are we treating here anyways?